A series of confirmed complete remissions at various doses in patients receiving Hanmi Pharmaceutical Co., Ltd.’s in-house-developed innovative drug for acute myeloid leukemia (AML), HM43239, are moving the once-daily, oral myeloid kinome inhibitor closer to registrational studies.
The drug is currently in an international Phase I/II trial in 34 patients with relapsed or refractory (R/R) AML who had received at least one prior line of therapy and...